81_CD Alliance_NNP UniChem_NNP Plc_NNP 18_CD IMPAIRMENT_NN TESTING_NN OF_IN GOODWILL_NNP AND_CC INTANGIBLE_NNP FIXED_VBD ASSETS_NNP WITH_IN INDEFINITE_NNP LIVES_NNP CONTINUED_VBD The_DT net_JJ book_NN value_NN of_IN retail_JJ pharmacy_NN licences_NNS by_IN these_DT segments_NNS were_VBD as_IN follows_VBZ :_: 2005_CD 2004_CD million_CD million_CD UK_NNP 579.7_CD 486.6_CD The_DT Netherlands_NNP 101.0_CD 103.8_CD Other_JJ 75.5_CD 74.6_CD Indefinite_JJ lives_NNS 756.2_CD 665.0_CD Subject_NNP to_TO amortisation_VB 25.5_CD 26.5_CD 781.7_CD 691.5_CD Goodwill_NNP and_CC retail_JJ pharmacy_NN licences_NNS are_VBP subject_JJ to_TO annual_JJ impairment_NN testing_NN ,_, or_CC more_RBR frequently_RB if_IN there_EX are_VBP indications_NNS of_IN impairment_NN ._.
The_DT recoverable_JJ amounts_NNS of_IN the_DT CGUs_NNS are_VBP determined_VBN from_IN value-in-use_JJ calculations_NNS which_WDT use_VBP amounts_NNS from_IN the_DT approved_VBN budgets_NNS and_CC plans_NNS ._.
The_DT discount_NN rate_NN applied_VBN to_TO the_DT cash_NN flow_NN projections_NNS was_VBD 8_CD %_NN 2004_CD 8_CD %_NN ._.
Average_JJ growth_NN rates_NNS used_VBN to_TO extrapolate_VB cash_NN flows_NNS beyond_IN the_DT approved_VBN budget_NN and_CC plan_NN period_NN were_VBD determined_VBN with_IN reference_NN to_TO the_DT CGUs_NNS country_NN of_IN operation_NN and_CC business_NN segment_NN ,_, and_CC ranged_VBD from_IN 1_CD %_NN to_TO 2_CD %_NN 2004_CD 1_CD %_NN to_TO 2_CD %_NN ._.
The_DT respective_JJ growth_NN rates_NNS did_VBD not_RB exceed_VB the_DT average_JJ long-term_JJ growth_NN rate_NN for_IN the_DT relevant_JJ market_NN ._.
